Cart
sales@molnova.com
Matuzumab
CAS No. 339186-68-4
Matuzumab( —— )
Catalog No. M22153 CAS No. 339186-68-4
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 544 | In Stock |
|
| 10MG | 778 | In Stock |
|
| 25MG | 1188 | In Stock |
|
| 50MG | 1572 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMatuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionMatuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
-
DescriptionMatuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number339186-68-4
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rob C. Roovers, et al. A bi-paratopic anti-EGFR nanobody efficiently inhibits solid tumour growth.Int J Cancer. 2011 Oct 15; 129(8): 2013–2024.
molnova catalog
related products
-
AG-1517
PD153035 hydrochloride is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.
-
RO 46-8443
RO 46-8443 is the first non-peptide endothelin ETB receptor selective antagonist. RO 46-8443 displays up to 2000-fold selectivity for ETB receptors both in terms of binding inhibitory potency and functional inhibition.
-
JBJ-04-125-02
JBJ-04-125-02 (0-1000 nM; 72 hours; H1975 cells) treatment could inhibit cell proliferation of H1975 cells at low nanomolar concentrations.
